Which epidermal growth factor receptor inhibitor is beneficial for a patient with cancer?
Erlotinib (Tarceva®) is approved for the treatment of patients with metastatic NSCLC and metastatic pancreatic cancer. Although its mechanism of action is not fully characterized, it is believed to selectively and reversibly inhibit the intracellular phosphorylation of EGFR tyrosine kinase.
What is epidermal growth factor receptor inhibitor?
A substance that blocks the activity of a protein called epidermal growth factor receptor (EGFR). EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide.
How do epidermal growth factor receptors trigger cancer cell production?
Sometimes, mutations (changes) in the EGFR gene cause epidermal growth factor receptor proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly.
What does the epidermal growth factor receptor do?
The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in regulating cell proliferation, survival, differentiation and migration. The ErbB receptors carry out both redundant and restricted functions in mammalian development and in the maintenance of tissues in the adult mammal.
How do growth factor inhibitors work?
Cancer growth blockers are also called cancer growth inhibitors. They are a type of targeted cancer drug. Our body makes chemicals called growth factors that control cell growth. Cancer growth blockers work by blocking the growth factors that trigger cancer cells to divide and grow.
What is EGFR inhibitor therapy?
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies.
How are growth factors involved in cancer?
Growth factors can also influence normal cell differentiation, and constitutive activation of growth-promoting pathways in cancer cells can modulate the cell phenotype as well. Paracrine actions of growth factors and cytokines may also influence the stepwise series of genetic events that lead to malignancy.
Is Gefitinib a chemotherapy?
The use of cytotoxic chemotherapy is associated with a response rate of 20 to 35% and a median survival time of 10 to 12 months among patients with advanced non–small-cell lung cancer. Gefitinib is an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR).
Is Gefitinib a monoclonal antibody?
Gefitinib and erlotinib are administered orally, once daily, so would be more suitable for an outpatient setting. In contrast, cetuximab is administered intravenously and, as it is a chimeric human–mouse monoclonal antibody, it can cause allergic reactions (Ciardiello and Tortora, 2001; Baselga, 2002).
What is angiogenesis therapy?
Angiogenesis means the growth of new blood vessels. So anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.
What types of drugs are EGFR inhibitors?
Currently available EGFR-inhibiting drugs include the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, and lapatinib, which are administered orally and interfere with the intracellular tyrosine kinase domain, and the monoclonal antibodies (mAbs) cetuximab and panitumumab, which are administered intravenously and …
What is VEGF and EGFR?
On the basis of preclinical and clinical evidence, EGFR, HER2 and VEGF represent validated targets for cancer therapy and remain the subject of intensive investigation. Both EGFR and HER2 are targets found on cancer cells, whereas VEGF is a target that acts in the tumour microenvironment.
Do cancer cells respond to growth inhibitors?
Its development and progression are usually linked to a series of changes in the activity of cell cycle regulators. For example, inhibitors of the cell cycle keep cells from dividing when conditions aren’t right, so too little activity of these inhibitors can promote cancer.